^
Association details:
Biomarker:MCL1 expression
Cancer:Diffuse Large B Cell Lymphoma
Drug:S63845 (MCL1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

TARGETING ANTI-APOPTOTIC MCL1 PROTEIN WITH S63845 IS HIGHLY EFFECTIVE IN AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMAS WITH NON-EXPRESSION OF BCL2

Published date:
06/12/2020
Excerpt:
...while the total level of MCL1 expression did not correlate with sensitivity to S63845, the occupational status of MCL1 with proapoptotic proteins proved as an important determinant of S63845 sensitivity...co-targeting of MCL1 and BCL2 (with S63845 and venetoclax) induced additive to synergistic anti-lymphoma effect in all tested PDX models. The data represent preclinical substantiation for novel salvage therapy of this prognostically adverse group of B-NHL patients.